Copy to clipboard 
Globus Medical reported 1Q25 orthopedic sales of $598.1 million, down 1.4% compared to the first quarter of 2024.
The company experiences softer enabling technology sales based on a difficult comps against a record first quarter last year as well as elongated selling cycles due to market uncertainty.
Additionally, supply chain disruption resulting from moving NuVasive products into Globus processes and timing of international distributor orders created headwinds during the first quarter.
In the face of those challenges, however, Globus’ U.S. spine business did manage modest growth. Early indications from the second quarter are good, with the company resuming above-market growth.
The company said it heard some anecdotal reports from surgeons that spine market volume is slowing.
“Having talked to surgeons, one of the things that they had told us is they saw some slowdown occurring, ” said Globus CEO Dan Scavilla. “They also felt like some of the approvals were taking longer from insurance companies as they’re going through it. But that was more conversational.”
Globus closed its acquisition of Nevro early in the second quarter. Inclusive of that acquisition, the company expects 2025 total sales between $2.8 billion and $2.9 billion, with no material impact from tariffs.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $517.8 | $511.7 | $6.1 | 1.2% |
| Trauma | $23.6 | $25.7 | ($2.0) | (8%) |
| Orthobiologics | $34.6 | $37.4 | ($2.8) | (7.5%) |
| Enabling Technology | $22.2 | $32.0 | ($9.8) | (30.6%) |
| Total | $598.1 | $606.7 | ($8.5) | (1.4%) |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $483.9 | $482.9 | $0.9 | 0.2% |
| OUS | $114.3 | $123.7 | ($9.5) | (7.7%) |
| Total | $598.1 | $606.7 | ($8.5) | (1.4%) |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $598.1 | |
| Cost of Sales | $195.4 | 32.7% |
| R & D | $33.1 | 5.5% |
| Selling and Admin | $242.8 | 40.6% |
| Other | $51.4 | 8.6% |
| Net Earnings | $75.5 | 12.6% |
Globus Medical reported 1Q25 orthopedic sales of $598.1 million, down 1.4% compared to the first quarter of 2024.
The company experiences softer enabling technology sales based on a difficult comps against a record first quarter last year as well as elongated selling cycles due to market uncertainty.
Additionally, supply chain...
Globus Medical reported 1Q25 orthopedic sales of $598.1 million, down 1.4% compared to the first quarter of 2024.
The company experiences softer enabling technology sales based on a difficult comps against a record first quarter last year as well as elongated selling cycles due to market uncertainty.
Additionally, supply chain disruption resulting from moving NuVasive products into Globus processes and timing of international distributor orders created headwinds during the first quarter.
In the face of those challenges, however, Globus’ U.S. spine business did manage modest growth. Early indications from the second quarter are good, with the company resuming above-market growth.
The company said it heard some anecdotal reports from surgeons that spine market volume is slowing.
“Having talked to surgeons, one of the things that they had told us is they saw some slowdown occurring, ” said Globus CEO Dan Scavilla. “They also felt like some of the approvals were taking longer from insurance companies as they’re going through it. But that was more conversational.”
Globus closed its acquisition of Nevro early in the second quarter. Inclusive of that acquisition, the company expects 2025 total sales between $2.8 billion and $2.9 billion, with no material impact from tariffs.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $517.8 | $511.7 | $6.1 | 1.2% |
| Trauma | $23.6 | $25.7 | ($2.0) | (8%) |
| Orthobiologics | $34.6 | $37.4 | ($2.8) | (7.5%) |
| Enabling Technology | $22.2 | $32.0 | ($9.8) | (30.6%) |
| Total | $598.1 | $606.7 | ($8.5) | (1.4%) |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $483.9 | $482.9 | $0.9 | 0.2% |
| OUS | $114.3 | $123.7 | ($9.5) | (7.7%) |
| Total | $598.1 | $606.7 | ($8.5) | (1.4%) |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $598.1 | |
| Cost of Sales | $195.4 | 32.7% |
| R & D | $33.1 | 5.5% |
| Selling and Admin | $242.8 | 40.6% |
| Other | $51.4 | 8.6% |
| Net Earnings | $75.5 | 12.6% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
